Atypical endocrine manifestations in Gordon syndrome caused by CUL3 mutation: a case report

• by Mahsa Fatahichegeni, Mohammad Amin Ansarian, Hongjun Lv, Jiao Fu

• July 20, 2026

FDA Approves First Therapy to Reduce Pancreatitis Risk

In two placebo-controlled trials, triglyceride levels declined by up to 72% compared with placebo.

• by Kathryn Wighton

• June 24, 2026

• 2 min

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

• by Kathryn Wighton

• July 16, 2026

• 2 min

Association of age at menopause with cardiovascular disease and mortality:insights from NHANES and a clinical cohort

• by Xinmiao Hong, Linxi Jin, Guoli Shang, Qiwei Chen, Zhuang Han, Shuhong Yao, Zhita Wang, Liang Li, Weidong He, Xianpei Heng, Liuqing Yang

• June 23, 2026